References
- Bizzarri M, Fuso A, Dinicola S, et al. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metab Toxicol. 2016;12(10):1181–1196. DOI: https://doi.org/10.1080/17425255.2016.1206887. PubMed PMID: 27351907 .
- De Meyts P, et al. The insulin receptor and its signal transduction network. Feingold KR, Anawalt B, Boyce A, editors Endotext. South Dartmouth (MA): MDText.com, Inc; 2000. Copyright © 2000-2020
- Shawl AI, Park K-H, Kim U-H. Insulin receptor signaling for the proliferation of pancreatic β-cells: involvement of Ca2+ Ca 2+ second messengers, IP3IP 3, NAADP and cADPR. Islets. 2009;1(3):216–223.
- Saltiel AR, Cuatrecasas P. Insulin stimulates the generation from hepatic plasma membranes of modulators derived from an inositol glycolipid. Proc Natl Acad Sci U S A. 1986;83(16):5793–5797. PubMed PMID: 3016721; PubMed Central PMCID: PMCPMC386381. eng. DOI:https://doi.org/10.1073/pnas.83.16.5793.
- Larner J, Huang LC, Schwartz CFW, et al. Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphatase contains galactosamine and D-chiroinositol. Biochem Biophys Res Commun. 1988;151(3):1416–1426.
- Larner J, Huang LC, Tang G, et al. Insulin mediators: structure and formation. Cold Spring Harb Symp Quant Biol. 1988;53:965–971. PubMed PMID: 3076102; eng. DOI:https://doi.org/10.1101/sqb.1988.053.01.111
- Sun T-HT-H, Heimark DB, Nguygen T, et al. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002;293(3):1092–82001–5. PubMed PMID: 12051772; eng. DOI:https://doi.org/10.1016/s0006-291x(02)00313-310.1210/jcem.83.6.4886
- Kennington AS, Hill CR, Craig J, et al. Low urinary chiro-inositol chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1990;323(6):373–378.
- Larner J, Craig JW. Urinary myo-inositol-to-chiro-inositol myo -Inositol-to-chiro -Inositol Ratios and Insulin Resistance. Diabetes Care. 1996;19(1):76–78. PubMed PMID: 8720541; eng. DOI:https://doi.org/10.2337/diacare.19.1.76.
- Hong JH, Jang HW, Kang YE, et al. Urinary chiro- and myo-inositol levels as a biological marker for type 2 diabetes mellitus. Dis Markers. 2012;33(4):193–199. PubMed PMID: 22960342; PubMed Central PMCID: PMCPMC3810682. eng. DOI:https://doi.org/10.3233/dma-2012-0925.
- Kawa JM, Przybylski R, Taylor CG. Urinary chiro-inositol and myo-inositol excretion is elevated in the diabetic db/db mouse and streptozotocin diabetic rat. Exp Biol Med. 2003;228(8):907–914.
- Baillargeon J-P, Diamanti-Kandarakis E, Ostlund RE, et al. Altered D-chiro-inositol D- chiro -inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006;29(2):300–305. DOI:https://doi.org/10.2337/diacare.29.02.06.dc05-1070.
- Arner RJ, Prabhu KS, Thompson JT, et al. myo-Inositol oxygenase: molecular cloning and expression of a unique enzyme that oxidizes myo-inositol and D-chiro-inositol. Biochem J. 2001;360(2):313–320. PubMed PMID: 11716759; eng. DOI:https://doi.org/10.1042/0264-6021:3600313
- Villeneuve MC, Ostlund RE Jr., Baillargeon JP. Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity. Metabolism. 2009;58(1):62–68. PubMed PMID: 19059532; eng. DOI:https://doi.org/10.1016/j.metabol.2008.08.007.
- Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011;95(8):2515–2516. DOI:https://doi.org/10.1016/j.fertnstert.2011.05.027. PubMed PMID: 21641593.
- Rojas J, Chávez M, Olivar L, et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod MedInternational Journal of Reproductive Medicine. 2014;2014:719050. PubMed PMID: 25763405; eng. DOI:https://doi.org/10.1155/2014/719050
- Nestler JE, Strauss JF. Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin North Am. 1991;20(4):807–823.
- Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83(6):2001–2005. DOI: https://doi.org/10.1210/jcem.83.6.4886. PubMed PMID: 9626131 .
- Nestler JE. Inositolphosphoglycans (IPGs) as mediators of insulin’s steroidogenic actions. J Basic Clin Physiol Pharmacol. 1998;9(2–4):197–204. PubMed PMID: 10212834; eng. DOI:https://doi.org/10.1515/jbcpp.1998.9.2-4.197
- Sacchi S, Marinaro F, Tondelli D, et al. Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol. Reprod Biol Endocrinol. 2016;14(1):52. PubMed PMID: 27582109; PubMed Central PMCID: PMCPMC5006365. eng. DOI:https://doi.org/10.1186/s12958-016-0189-2
- Lagana AS, Unfer V. D-Chiro-Inositol’s action as aromatase inhibitor: rationale and potential clinical targets. Eur Rev Med Pharmacol Sci. 2019;23(24):10575–10576. PubMed PMID: 31858524; eng. DOI:https://doi.org/10.26355/eurrev_201912_19752
- Cheang KI, Baillargeon JP, Essah PA, et al. Insulin-stimulated release of D-chiro-inositol-containing inositol phosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism. 2008;57(10):1390–1397. PubMed PMID: 18803944; PubMed Central PMCID: PMCPMC2574418. eng. DOI:https://doi.org/10.1016/j.metabol.2008.05.008
- Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D- chiro -inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340(17):1314–1320. PubMed PMID: 10219066; eng. DOI:https://doi.org/10.1056/nejm199904293401703.
- Bevilacqua A, Dragotto J, Lucarelli M, et al. High doses of d-chiro-inositol alone induce a pco-like syndrome and other alterations in mouse ovaries. Int J Mol Sci. 2021;22(11):5691. DOI: https://doi.org/10.3390/ijms22115691. PubMed PMID: 34073634; PubMed Central PMCID: PMCPMC8198710 .
- Thomas RM, Nechamen CA, Mazurkiewicz JE, et al. The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2+) mobilization. Endocrinology. 2011;152(4):1691–1701. PubMed PMID: 21285318; PubMed Central PMCID: PMCPMC3060640. eng. DOI:https://doi.org/10.1210/en.2010-1353.
- Milewska EM, Czyzyk A, Meczekalski B, et al. Inositol and human reproduction. From cellular metabolism to clinical use. Gynecol Endocrinol. 2016;32(9):690–695.
- Laganà AS, Vitagliano A, Noventa M, et al. Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018;298(4):675–684. DOI: https://doi.org/10.1007/s00404-018-4861-y. PubMed PMID: 30078122 .
- Unfer V, Benvenga S. Letter to the Editor - Myo-inositol and dominant follicle. International Journal of Medical Device and Adjuvant Treatments. 2016;1:1.
- Stocco C. Aromatase expression in the ovary: hormonal and molecular regulation. Steroids. 2008;73(5):473–487.
- Steinkampf MP, Mendelson CR, Simpson ER. Regulation by follicle-stimulating hormone of the synthesis of aromatase cytochrome P-450 in human granulosa cells. Mol Endocrinol. 1987;1(7):465–471. PubMed PMID: 3155262; eng. DOI:https://doi.org/10.1210/mend-1-7-465.
- Zeleznik AJ, Saxena D, Little-Ihrig L. protein kinase b is obligatory for follicle-stimulating hormone-induced granulosa cell differentiation. Endocrinology. 2003;144(9):3985–3994.
- Nestler JE, Romero G, Huang LC, et al. insulin mediators are the signal transduction system responsible for insulin’s actions on human placental steroidogenesis. Endocrinology. 1991;129(6):2951–2956.
- Unfer V, Forte G. Does inositol ratio orchestrate the fate of ovarian follicles? Med Hypotheses. 2020;144:109983. DOI:https://doi.org/10.1016/j.mehy.2020.109983. PubMed PMID: 32540608; eng.
- Heimark D, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2014;61(2):111–117. PubMed PMID: 24189751. DOI:https://doi.org/10.1507/endocrj.EJ13-0423.
- Hillier SG, Reichert LE, Van Hall JR. Control of preovulatory follicular estrogen biosynthesis in the human ovary. J Clin Endocrinol Metab. 1981;52(5):847–856.
- Unfer V, Dinicola S, Laganà AS, et al. Altered ovarian inositol ratios may account for pathological steroidogenesis in PCOS. Int J Mol Sci. 2020:21. DOI:https://doi.org/10.3390/ijms21197157. PubMed PMID: 32998310; PubMed Central PMCID: PMCPMC7582282. eng.
- The Rotterdam easpcwg. reVised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47. DOI:https://doi.org/10.1093/humrep/deh098
- Zhou P, Baumgarten SC, Wu Y, et al. IGF-I signaling is essential for FSH stimulation of AKT and steroidogenic genes in granulosa cells. Mol Endocrinol. 2013;27(3):511–523. PubMed PMID: 23340251; eng. DOI:https://doi.org/10.1210/me.2012-1307.
- Chiu TTY, Rogers MS, Law ELK, et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002;17(6):1591–1596.
- Ravanos K, Monastra G, Pavlidou T, et al. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? Eur Rev Med Pharmacol Sci. 2017;21(23):5491–5498. DOI: https://doi.org/10.26355/eurrev_201712_13940. PubMed PMID: 29243796 .
- Laganà AS, Garzon S, Casarin J, et al. Inositol in Polycystic Ovary Syndrome: restoring Fertility through a Pathophysiology-Based Approach. Trends Endocrinol Metab. 2018;29(11):768–780.
- Unfer V, Carlomagno G, Papaleo E, et al. Hyperinsulinemia alters myoinositol to d-chiroinositol d -chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci. 2014;21(7):854–858. PubMed PMID: 24501149. DOI:https://doi.org/10.1177/1933719113518985
- Minini M, Monastra G, Dinicola S. A double-edge sword: the role of D-chiro-inositol in oocyte and embryo quality. International Journal of Medical Device and Adjuvant Treatments. 2019;2:e208.
- Facchinetti F, Appetecchia M, Aragona C, et al. Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. Expert Opin Drug Metab Toxicol. 2020;16(3):255–274. DOI:https://doi.org/10.1080/17425255.2020.1737675.
- Facchinetti F, Dante G, Neri I. The ratio of mi to dci and its impact in the treatment of polycystic ovary syndrome: experimental and literature evidences. In: Genazzani AR, Tarlatzis BC, editors. Frontiers in gynecological endocrinology: volume 3: ovarian function and reproduction - from needs to possibilities. Cham: Springer International Publishing; 2016. p. 103–109.
- Bevilacqua A, Dragotto J, Giuliani A, et al. Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J Cell Physiol. 2019;234(6):9387–9398.
- Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23(12):5512–5521. PubMed PMID: 31298405; eng. DOI:https://doi.org/10.26355/eurrev_201906_18223
- La Marca A, Morgante G, Palumbo M, et al. Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril. 2002;78(6):1234–1239. PubMed PMID: 12477517; eng. DOI:https://doi.org/10.1016/s0015-0282(02)04346-7.
- Shaw ND, Histed SN, Srouji SS, et al. Estrogen negative feedback on gonadotropin secretion: evidence for a direct pituitary effect in women. J Clin Endocrinol Metab. 2010;95(4):1955–1961. PubMed PMID: 20133465; eng. DOI:https://doi.org/10.1210/jc.2009-2108
- Penzias A, Bendikson K, Butts S. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline.Fertil Steril. 2017;108:426–441.
- Nakamura Y, Ono M, Yoshida Y, et al. Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. Fertil Steril. 1997;67(2):256–260. PubMed PMID: 9022599; eng. DOI:https://doi.org/10.1016/s0015-0282(97)81907-3
- Randall JM, Templeton A. Cervical mucus score and in vitro sperm mucus interaction in spontaneous and clomiphene citrate cycles. Fertil Steril. 1991;56(3):465–468. PubMed PMID: 1894023; eng. DOI:https://doi.org/10.1016/s0015-0282(16)54541-5
- Dickey RP, Olar TT, Taylor SN, et al. Relationship of endometrial thickness and pattern to fecundity in ovulation induction cycles: effect of clomiphene citrate alone and with human menopausal gonadotropin. Fertil Steril. 1993;59(4):756–760. PubMed PMID: 8458492; eng. DOI:https://doi.org/10.1016/s0015-0282(16)55855-5.
- Kamenov Z, Kolarov G, Gateva A, et al. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol. 2015;31(2):131–135. PubMed PMID: 25259724; eng. DOI:https://doi.org/10.3109/09513590.2014.964640
- Nestler JE, Gunn R, Bates S, et al. D-<em>chiro</em>-inositol (INS-1) enhances ovulatory rate in hyperandrogenemic, oligomenorrheic women with the polycystic ovary syndrome. Fertil Steril. 2001;76:S110–S111. DOI: https://doi.org/10.1016/S0015-0282(01)02325-1.
- Gambioli R, Forte G, Aragona C, et al. The use of D-chiro-Inositol in clinical practice. Eur Rev Med Pharmacol Sci. 2021Jan;251:438–446. DOI: https://doi.org/10.26355/eurrev_202101_24412. PubMed PMID: 33506934; eng
- Laganà AS, Garzon S, Unfer V. New clinical targets of d-chiro-inositol: rationale and potential applications. Expert Opin Drug Metab Toxicol. 2020; 1–7. PubMed PMID: 32552009; eng. DOI: https://doi.org/10.1080/17425255.2020.1785429.
- Bizzarri M, Cucina A, Dinicola S, et al. Does myo-inositol effect on PCOS follicles involve cytoskeleton regulation? Med Hypotheses. 2016;91:1–5.
- Pkhaladze L, Barbakadze L, Kvashilava N. Myo-Inositol in the Treatment of Teenagers Affected by PCOS. Int J Endocrinol. 2016;2016:1473612.
- Zacche MM, Caputo L, Filippis S, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25(8):508–513. PubMed PMID: 19551544; eng. DOI:https://doi.org/10.1080/09513590903015544.
- Unfer V, Facchinetti F, Orru B, et al. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–658. PubMed PMID: 29042448; eng. DOI:https://doi.org/10.1530/ec-17-0243.
- Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013;29(4):375–379. PubMed PMID: 23336594; eng. DOI:https://doi.org/10.3109/09513590.2012.743020.
- Costantino D, Minozzi G, Minozzi E, et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 20092012;13(2):105–10193–199. PubMed PMID: 19499845; eng.
- Genazzani AD, Lanzoni C, Ricchieri F, et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24(3):139–144. PubMed PMID: 18335328; eng. DOI:https://doi.org/10.1080/09513590801893232.
- Gerli S, Papaleo E, Ferrari A, et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11(5):347–354.
- Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol d -chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol. 2014;30(3):205–208.
- Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012;16(5):575–581. PubMed PMID: 22774396; eng.
- Benelli E, Del Ghianda S, Di Cosmo C , et al. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. 2016; 2016: 3204083 doi:https://doi.org/10.1155/2016/3204083 .
- Ozay A, Emekci Ozay O, Emre Okyay R, et al. Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women. 2016; 2016: 3206872 doi:https://doi.org/10.1155/2016/3206872 .
- Zeng L, Yang K. Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018;59(1):30–38.
- Takeuchi T, Tsutsumi O, Taketani Y. Abnormal response of insulin to glucose loading and assessment of insulin resistance in non-obese patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24(7):385–391.
- Macut D, Simic T, Lissounov A, et al. Insulin resistance in non-obese women with polycystic ovary syndrome: relation to byproducts of oxidative stress. Exp Clin Endocrinol Diabetes. 2011;119(7):451–455. En. DOI:https://doi.org/10.1055/s-0031-1279740.
- Diamanti-Kandarakis E, Alexandraki K, Bergiele A, et al. Presence of metabolic risk factors in non-obese PCOS sisters: evidence of heritability of insulin resistance. J Endocrinol Invest. 2004;27(10):931–936. PubMed PMID: 15762040; eng. DOI:https://doi.org/10.1007/bf03347535.
- Donà G, Sabbadin C, Fiore C, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(4):703–710. PubMed PMID: 22223702; eng. DOI:https://doi.org/10.1530/eje-11-0840.
- Monastra G, Unfer V, Harrath AH, et al. Combining treatment with myo-inositol and D-chiro-inositol (40: 1) 40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecol Endocrinol. 2017;33(1):1–9. DOI:https://doi.org/10.1080/09513590.2016.1247797.
- Roseff S, Montenegro M. Inositol treatment for PCOS should be science-based and not arbitrary. Int J Endocrinol. 2020;2020:6461254. DOI:https://doi.org/10.1155/2020/6461254. PubMed PMID: 32308679; PubMed Central PMCID: PMCPMC7140126. eng.
- Pintaudi B, Di Vieste G, Bonomo M. The effectiveness of myo-inositol and D-Chiro Inositol Treatment in Type 2 Diabetes. Int J Endocrinol. 2016;2016:9132052.
- Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013;17:537–540. PubMed PMID: 23467955; eng.
- Chiu TTY, Rogers MS, Briton‐Jones C, et al. Effects of myo‐inositol on the in‐vitro maturation and subsequent development of mouse oocytes. Hum Reprod. 2003;18(2):408–416. DOI:https://doi.org/10.1093/humrep/deg113.
- Özay Ö E, Özay AC, Çağlıyan E, et al. Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial. Gynecol Endocrinol. 2017;33(7):524–528. PubMed PMID: 28277112; eng. DOI:https://doi.org/10.1080/09513590.2017.1296127.
- Facchinetti F, Espinola MSB, Dewailly D, et al. Breakthroughs in the use of inositols for assisted reproductive treatment (ART). Trends Endocrinol Metab. 2020;31(8):570–579. PubMed PMID: 32418772; eng. DOI:https://doi.org/10.1016/j.tem.2020.04.003.
- Garzon S, Laganà AS, Monastra G. Risk of reduced intestinal absorption of myo-inositol caused by D-chiro-inositol or by glucose transporter inhibitors. Expert Opin Drug Metab Toxicol. 2019;15(9):697–703.
- Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1(2):57–92. PubMed PMID: 22127746; PubMed Central PMCID: PMCPMC3138482. eng. DOI:https://doi.org/10.1007/s13300-010-0006-4.
- Groenen PM, Merkus HM, Sweep FC, et al. Kinetics of myo-inositol myoinositol loading in women of reproductive age. Ann Clin Biochem. 2003;40(1):79–85. PubMed PMID: 12542915; eng. DOI:https://doi.org/10.1258/000456303321016213.
- Orrù B, Circo R, Logoteta P, et al. Finding the best therapeutic approach for PCOS: the importance of inositol(s) bioavailability. Eur Rev Med Pharmacol Sci. 2017;21(2 Suppl):83–88. PubMed PMID: 28724181; eng.
- Dinicola S, Minini M, Unfer V, et al. Nutritional and acquired deficiencies in inositol bioavailability. Correlations with Metabolic Disorders. Int J Mol Sci. 2017;18. 2187.
- Monastra G, Ferruzza S, Sambuy Y, et al. Alpha-lactalbumin effect on myo-inositol intestinal absorption: in vivo and in vitro. Curr Drug Deliv. 2018:8. DOI:https://doi.org/10.2174/1567201815666180509102641. PubMed PMID: 29745333; eng.
- Facchinetti F, Unfer V, Dewailly D, et al. Inositols in polycystic ovary syndrome: an overview on the advances. Trends Endocrinol Metab. 2020;31(6):435–447. PubMed PMID: 32396844; eng. DOI:https://doi.org/10.1016/j.tem.2020.02.002
- Ranaldi G, Ferruzza S, Natella F, et al. Enhancement of D-chiro-inositol transport across intestinal cells by alpha-Lactalbumin peptides. Eur Rev Med Pharmacol Sci. 2020;24(19):10143–10154. PubMed PMID: 33090422; eng. DOI:https://doi.org/10.26355/eurrev_202010_23234.
- Montanino Oliva M, Buonomo G, Calcagno M, et al. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. J Ovarian Res. 2018;11(1):38. doi: https://doi.org/10.1186/s13048-018-0411-2. PubMed PMID: 29747700 .
- Monastra G, Vucenik I, Harrath AH, et al. PCOS and inositols: controversial results and necessary clarifications. basic differences between d-chiro and myo-inositol. Front Endocrinol (Lausanne). 2021;12:660381. PubMed PMID: 33889133; PubMed Central PMCID: PMCPMC8056130. eng. DOI:https://doi.org/10.3389/fendo.2021.660381.
- Vazquez-Levin MH, Verón GL. Myo-inositol in health and disease: its impact on semen parameters and male fertility. Andrology. 2020;8(2):277–298. PubMed PMID: 31637826; eng. DOI:https://doi.org/10.1111/andr.12718.
- Governini L, Ponchia R, Artini PG, et al. Respiratory mitochondrial efficiency and DNA oxidation in human sperm after in vitro myo-inositol treatment. J Clin Med. 2020;9(6):1638.
- Ponchia R, Bruno A, Renzi A, et al. oxidative stress measurement in frozen/thawed human sperm: the protective role of an in vitro treatment with myo-inositol. Antioxidants (Basel). 2021;11(1):11. PubMed PMID: 35052514; PubMed Central PMCID: PMCPMC8773045. eng. DOI:https://doi.org/10.3390/antiox11010010.